FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3006596667> ?p ?o ?g. }

• W3006596667 endingPage "598" @default.
• W3006596667 startingPage "586" @default.
• W3006596667 abstract "Abstract The selective inhibitor of nuclear export (SINE) compounds selinexor (KPT-330) and eltanexor (KPT-8602) are from a novel class of small molecules that target exportin-1 (XPO1 [CRM1]), an essential nucleo-cytoplasmic transport protein responsible for the nuclear export of major tumor suppressor proteins and growth regulators such as p53, p21, and p27. XPO1 also affects the translation of messenger RNAs for critical oncogenes, including MYC, BCL2, MCL1, and BCL6, by blocking the export of the translation initiation factor eIF4E. Early trials with venetoclax (ABT-199), a potent, selective inhibitor of BCL2, have revealed responses across a variety of hematologic malignancies. However, many tumors are not responsive to venetoclax. We used models of acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL) to determine in vitro and in vivo responses to treatment with venetoclax and SINE compounds combined. Cotreatment with venetoclax and SINE compounds demonstrated loss of viability in multiple cell lines. Further in vitro analyses showed that this enhanced cell death was the result of an increase in apoptosis that led to a loss of clonogenicity in methylcellulose assays, coinciding with activation of p53 and loss of MCL1. Treatment with SINE compounds and venetoclax combined led to a reduction in tumor growth in both AML and DLBCL xenografts. Immunohistochemical analysis of tissue sections revealed that the reduction in tumor cells was partly the result of an induction of apoptosis. The enhanced effects of this combination were validated in primary AML and DLBCL patient cells. Our studies reveal synergy with SINE compounds and venetoclax in aggressive hematologic malignancies and provide a rationale for pursuing this approach in a clinical trial." @default.
• W3006596667 created "2020-02-24" @default.
• W3006596667 creator A5002284472 @default.
• W3006596667 creator A5009364549 @default.
• W3006596667 creator A5015865144 @default.
• W3006596667 creator A5019724193 @default.
• W3006596667 creator A5038643879 @default.
• W3006596667 creator A5046823186 @default.
• W3006596667 creator A5049400849 @default.
• W3006596667 creator A5051352882 @default.
• W3006596667 creator A5057755017 @default.
• W3006596667 creator A5061092393 @default.
• W3006596667 creator A5061973648 @default.
• W3006596667 creator A5064653083 @default.
• W3006596667 creator A5064840115 @default.
• W3006596667 creator A5067532930 @default.
• W3006596667 creator A5069962551 @default.
• W3006596667 creator A5071649423 @default.
• W3006596667 creator A5075664149 @default.
• W3006596667 creator A5086110064 @default.
• W3006596667 date "2020-02-11" @default.
• W3006596667 modified "2023-10-18" @default.
• W3006596667 title "Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies" @default.
• W3006596667 cites W1598054001 @default.
• W3006596667 cites W1696775091 @default.
• W3006596667 cites W1721974233 @default.
• W3006596667 cites W1952112347 @default.
• W3006596667 cites W1964824076 @default.
• W3006596667 cites W1968110789 @default.
• W3006596667 cites W1974073852 @default.
• W3006596667 cites W1976720365 @default.
• W3006596667 cites W1987452803 @default.
• W3006596667 cites W2009386327 @default.
• W3006596667 cites W2017630738 @default.
• W3006596667 cites W2028766709 @default.
• W3006596667 cites W2046497407 @default.
• W3006596667 cites W2083470652 @default.
• W3006596667 cites W2093663447 @default.
• W3006596667 cites W2094088075 @default.
• W3006596667 cites W2096849855 @default.
• W3006596667 cites W2099655761 @default.
• W3006596667 cites W2102461774 @default.
• W3006596667 cites W2104519081 @default.
• W3006596667 cites W2115943711 @default.
• W3006596667 cites W2117692326 @default.
• W3006596667 cites W2136345410 @default.
• W3006596667 cites W2136910701 @default.
• W3006596667 cites W2161956550 @default.
• W3006596667 cites W2172242534 @default.
• W3006596667 cites W2176912713 @default.
• W3006596667 cites W2187721367 @default.
• W3006596667 cites W2192121806 @default.
• W3006596667 cites W2289284908 @default.
• W3006596667 cites W2290633618 @default.
• W3006596667 cites W2314303292 @default.
• W3006596667 cites W2338878406 @default.
• W3006596667 cites W2369297677 @default.
• W3006596667 cites W2400101856 @default.
• W3006596667 cites W2414615618 @default.
• W3006596667 cites W2419091909 @default.
• W3006596667 cites W2439067156 @default.
• W3006596667 cites W2495597122 @default.
• W3006596667 cites W2517675534 @default.
• W3006596667 cites W2520937393 @default.
• W3006596667 cites W2533094307 @default.
• W3006596667 cites W2534349779 @default.
• W3006596667 cites W2582696216 @default.
• W3006596667 cites W2602169105 @default.
• W3006596667 cites W2605114805 @default.
• W3006596667 cites W2606676276 @default.
• W3006596667 cites W2610540653 @default.
• W3006596667 cites W2741462465 @default.
• W3006596667 cites W2765358708 @default.
• W3006596667 cites W2772881286 @default.
• W3006596667 cites W2773114573 @default.
• W3006596667 cites W2783500974 @default.
• W3006596667 cites W2794340145 @default.
• W3006596667 cites W2872716351 @default.
• W3006596667 cites W2889850618 @default.
• W3006596667 cites W2891173371 @default.
• W3006596667 cites W2891248360 @default.
• W3006596667 cites W2892573863 @default.
• W3006596667 cites W2895841937 @default.
• W3006596667 cites W2922692686 @default.
• W3006596667 doi "https://doi.org/10.1182/bloodadvances.2019000359" @default.
• W3006596667 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7013257" @default.
• W3006596667 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32045477" @default.
• W3006596667 hasPublicationYear "2020" @default.
• W3006596667 type Work @default.
• W3006596667 sameAs 3006596667 @default.
• W3006596667 citedByCount "34" @default.
• W3006596667 countsByYear W30065966672020 @default.
• W3006596667 countsByYear W30065966672021 @default.
• W3006596667 countsByYear W30065966672022 @default.
• W3006596667 countsByYear W30065966672023 @default.
• W3006596667 crossrefType "journal-article" @default.
• W3006596667 hasAuthorship W3006596667A5002284472 @default.
• W3006596667 hasAuthorship W3006596667A5009364549 @default.

• next